Global Metastatic Breast Cancer Pipeline Insight Report 2021: Focus on 100+ Companies and 100+ Pipeline Drugs -

DUBLIN--()--The "Metastatic Breast Cancer - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.

Metastatic Breast Cancer Emerging Drugs Chapters

This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Breast Cancer Emerging Drugs

Giredestrant: Roche

Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).

Disitamab Vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.

EndoTAG-1 (SB05): SynCore Biotechnology

SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

Stenoparib (2X-121): Allarity Therapeutics

Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.

Major Players in Metastatic Breast Cancer

There are approx. 100+ key companies which are developing the therapies for Metastatic Breast Cancer. The companies which have their Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Roche.

Key Questions Answered

  • How many companies are developing Metastatic Breast Cancer drugs?
  • How many Metastatic Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Breast Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metastatic Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Roche
  • RemeGen
  • SynCore Biotechnology
  • Allarity Therapeutics
  • Daiichi Sankyo Company
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd
  • Byondis B.V.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Shanghai Miracogen Inc.
  • Ambrx, Inc.
  • Daehwa Pharmaceutical Co., Ltd.
  • Phoenix Molecular Designs
  • GlycoMimetics Incorporated
  • Rhizen Pharmaceuticals SA
  • Menarini Group
  • Samus Therapeutics, Inc.
  • Hanmi Pharmaceutical Company Limited
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • Immutep Limited
  • Arvinas Inc.
  • G1 Therapeutics
  • Mirati Therapeutics Inc.
  • Chia Tai Tianqing Pharmaceutical
  • Shanghai Pharmaceuticals Holding Co., Ltd
  • Pfizer
  • OncoTherapy Science, Inc.
  • Eisai Inc.
  • Dizal Pharmaceuticals
  • Jiangsu Hengrui Medicine Co.
  • Tyme, Inc
  • Orion Pharma
  • HiberCell, Inc.
  • Rhizen Pharmaceuticals SA
  • Hutchison Medipharma Limited
  • OncoPep Inc.
  • Taizhou Hanzhong biomedical co. LTD

Key Products

  • Giredestrant:
  • Disitamab Vedotin
  • EndoTAG-1 (SB05)
  • Stenoparib (2X-121)
  • U3-1402
  • KN026
  • trastuzumab duocarmazine
  • HS-10342
  • MRG002
  • ARX788
  • DHP107
  • PMD-026
  • GMI-1359
  • PVX-410
  • HX008
  • Tenalisib
  • MEN1611
  • SM-88
  • HMPL-013
  • ODM-209
  • HC-5404-FU
  • RP12146
  • PU-H71
  • NOV120101
  • SC10914
  • Eftilagimod Alpha
  • ARV-471
  • E7090
  • DZD1516
  • SHR6390
  • G1T38
  • Sitravatinib
  • TQ-B211
  • B003
  • PF-06873600
  • OTS167PO

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900